Autolus Therapeutics downgraded by Redburn
$AUTL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Redburn downgraded Autolus Therapeutics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2026 | $9.00 | Buy | H.C. Wainwright |
| 11/18/2024 | $7.00 → $7.60 | Neutral → Buy | Goldman |
| 11/15/2024 | $13.00 | Neutral → Buy | Redburn Atlantic |
| 11/9/2023 | $10.00 | Buy | Deutsche Bank |
| 3/27/2023 | $8.00 | Overweight | Wells Fargo |
| 3/17/2023 | $5.00 | Buy | Bryan Garnier |
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences. William Blair's 46th Annual Growth Stock ConferenceDate and time: June 2, 2026; 1:20pm CDT / 7:20pm BSTLocation: Chicago, ILPresenter: Chief Executive Officer Dr. Christian Itin Jefferies Global Healthcare ConferenceDate and time: June 3, 2026; 10:30am EDT / 3:30pm BSTLocation: New York, NYPresenter: Chief Executive Officer Dr. Christian Itin Webcasts of the pres
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. "Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LON
H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00
Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously
Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00
SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
10-Q - Autolus Therapeutics plc (0001730463) (Filer)
3 - Autolus Therapeutics plc (0001730463) (Issuer)
3 - Autolus Therapeutics plc (0001730463) (Issuer)
3 - Autolus Therapeutics plc (0001730463) (Issuer)
SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive gross margin for the acute lymphoblastic leukemia (ALL) business Cost reduction initiative to drive gross profit margin improvement and path to profitability for the ALL business underwayObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants should pre-register using the link at the bottom of this press release LON
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required
AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot
Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from
LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil